Case series shows eculizumab rapidly improves symptoms in treatment-resistant ocular myasthenia gravis, suggesting it as a viable option.
In patients with refractory ocular or ocular-predominant MG, eculizumab had a rapid onset of therapeutic effect that was sustained after 12 weeks, regardless of the antibody titer. The favorable safety profile supports its use in treatment-resistant cases of refractory OMG or ocular-predominant MG. Larger randomized controlled trials are needed to establish the long-term effectiveness and optimize treatment protocols.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: